NASDAQ:PTLA

Portola Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes novel therapeutics in the areas of thrombosis, and other hematologic disorders and inflammation in Europe and the United States. Its lead product Andexxa, an antidote for the treatment of rivaroxaban and apixaban under the Ondexxya Brand. The company offers Bevyxxa (betrixaban), an oral, once-daily Factor Xa inhibitor for the prevention of venous thromboembolism in adult patients for an acute medical illness. It also develops cerdulatinib, an investigational oral, dual spleen tyrosine kinase, and janus kinases inhibitor for the treatment of hematologic cancers; and Syk inhibitors. Portola Pharmaceuticals, Inc. has collaboration agreements with Bristol-Myers Squibb; Pfizer Inc.; Daiichi Sankyo, Inc.; Bayer Pharma, AG; Takeda, Ora, Inc.; Astellas Pharma Inc.; and Janssen Pharmaceuticals, Inc. The company was founded in 2003 and is headquartered in South San Francisco, California. As of July 1, 2020, Portola Pharmaceuticals, Inc. operates as a subsidiary of Alexion Pharmaceuticals, Inc.